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Abstract
The therapeutic effects of fullerene derivatives on many models of inflammatory disease have been demonstrated. The
anti-inflammatory mechanisms of these nanoparticles remain to be elucidated, though their beneficial roles in allergy
and autoimmune diseases suggest their suppressive potential in acquired immunity. Here, we evaluated the effects of
C60 pyrrolidine tris-acid (C60-P) and polyhydroxylated fullerene (C60(OH)36) on the acquired immune response in vitro
and in vivo. In vitro, both C60 derivatives had dose-dependent suppressive effects on T cell receptor-mediated
activation of T cells and antibody production by B cells under anti-CD40/IL-4 stimulation, similar to the actions of the
antioxidant N-acetylcysteine. In addition, C60-P suppressed ovalbumin-specific antibody production and ovalbumin-
specific T cell responses in vivo, although T cell-independent antibodies responses were not affected by C60-P.
Together, our data suggest that fullerene derivatives can suppress acquired immune responses that require T cells.
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Background
Fullerenes C60 and C70 are unique spherical carbon mol-
ecules. Fullerenes have a highly unsaturated structure
and excellent electron-receptor properties, and for these
reasons, these molecules—particularly water-soluble
fullerene derivatives in which hydrophilic group moieties
are added to the carbon cage for biological uses—have
been investigated extensively as radical scavengers [1].
Fullerene derivatives have many beneficial biological ef-
fects supposedly related to their antioxidant activity, in-
cluding liver protection [2], reduction of neuronal injury
[3, 4], extension of life span [5], and UV- and radiopro-
tection [6]. In addition, fullerenes have many potential
biological roles beyond their antioxidant activity, includ-
ing anti-HIV activity [7, 8] and enzyme inhibition [9].
Many studies have shown the anti-inflammatory
effects of fullerene derivatives, which are expected to be
candidates for use as anti-inflammatories [10–12]. How-
ever, despite the abundant evidence of these anti-
inflammatory effects, the mechanisms by which they
occur are not fully understood. The therapeutic effects
of fullerene derivatives on allergy [13] and on auto-
immune diseases [4, 14] suggest their suppressive poten-
tial in acquired immunity, but little is known about the
effects of these derivatives on acquired immunity. Here,
we explored the effects of fullerene derivatives on the ac-
quired immune response in vitro and in vivo by using
two hydrophilized C60 derivatives, namely C60 pyrroli-
dine tris-acid (C60-P) and polyhydroxylated fullerene
(C60(OH)36). Our data suggest that fullerene derivatives
can suppress acquired immune responses that require T




C60 pyrrolidine tris-acid (C66O6NH7) (C60-P) was pur-
chased from FLOX (Kanagawa, Japan). Polyhydroxylated
fullerene (C60(OH)36·8H2O; C60(OH)36) was synthesized
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as previously described [15]. We confirmed the purity
(95.3 %) of C60-P by using liquid chromatography–mass
spectrometry. C60(OH)36 is a mixture of isomers; we
prepared and purified it by using a method described in
the literature [15]. The C60 powders were stored in the
dark at room temperature. Immediately before use, the
powder was dispersed in dimethyl sulfoxide (Wako,
Osaka, Japan), sonicated at 400 W for 5 min at 25 °C,
and then vortexed for 1 min. This suspension was then
diluted with cell culture medium or saline, further soni-
cated at 400 W for 5 min at 25 °C, and then vortexed
for 1 min.
Reagents
Mitomycin C was purchased from Wako. Anti-mouse
CD3ε (145-2C11), CD28 (37.51), and CD40 (HM40-3)
were obtained from Biolegend (San Diego, CA, USA).
Recombinant mouse IL-4 was purchased from R&D Sys-
tems (Minneapolis, MN, USA). Ovalbumin (OVA), N-
acetylcysteine (NAC), and lipopolysaccharide (LPS;
Escherichia coli O55:B5) were purchased from Sigma–
Aldrich (St. Louis, MO, USA). NP49-AECM-Ficoll
(NP49-Ficoll; 4-hydroxy-3-nitrophenylacetic hapten
conjugated to amino-ethyl-carboxy-methyl-Ficoll) and
NP30-BSA were obtained from Biosearch Technologies
(Novato, CA, USA).
Mice
Female C57BL/6 and BALB/c mice were purchased from
SLC (Kyoto, Japan) and used at 6 to 8 weeks of age.
Mixed Lymphocyte Reactions (MLRs)
Responder splenocytes from BALB/c mice were seeded
onto 96-well flat-bottomed plates (Nunc, Roskilde,
Denmark) (1 × 106 cells/well). Stimulator splenocytes
from C57BL/6 mice were treated with 250 μg/mL mito-
mycin C at 37 °C for 30 min, followed by three extensive
washes with complete RPMI1640 supplemented with
10 % fetal bovine serum, 10 mL/L of a 100× nonessential
amino acid solution (Gibco, Invitrogen, Carlsbad, CA,
USA), 50 μM 2-mercaptoethanol (Gibco), and 1 % anti-
biotic cocktail (10,000 U/mL penicillin, 10,000 μg/mL
streptomycin, 25 μg/mL amphotericin B; Gibco). They
were then added at 3 × 106 cells/well to responder sple-
nocytes. C60-P or C60(OH)36 was added to responder
splenocytes 30 min before addition of the stimulator
splenocytes. After incubation of the cells for 4 days at
37 °C (95 % room air, 5 % CO2), the amount of interleu-
kin 2 (IL-2) released into an aliquot of culture super-
natant was measured with a murine IL-2 enzyme-linked
immunosorbent assay (ELISA) kit (eBioscience, San
Diego, CA, USA) in accordance with the manufacturer’s
instructions.
OVA-Specific Immune Response In Vitro
C57BL/6 mice were intraperitoneally immunized with
OVA (10 μg/mouse) and Imject Alum adjuvant (1 mg/
mouse) (Thermo Fisher Scientific K.K., Tokyo, Japan)
weekly. One week after the third injection, the mice were
euthanized, and single-cell suspensions of splenocytes
were prepared. C60-P or C60(OH)36 was added to the well
30 min before the addition of OVA (100 μg/mL). After in-
cubation of the cells for 3 days at 37 °C (95 % room air,
5 % CO2), the amount of interleukin-4 (IL-4) released into
an aliquot of culture supernatant was measured with an
IL-4 ELISA kit (eBioscience) in accordance with the
manufacturer’s instructions.
T cell stimulation assay
To stimulate CD4+ T cells, we coated 96-well flat-
bottomed plates (Nunc) with anti-CD3ε (2.5 μg/mL) by
overnight incubation at 4 °C. CD4+ T cells were nega-
tively isolated with a CD4+ T cell isolation kit (Miltenyi
Biotec, Bergisch-Gladbach, Germany) in accordance with
the manufacturer’s instructions. CD4+ T cell purity was
determined by flow cytometry (CD3+, CD4+ cells >90 %
purification). Immediately after cell preparation, CD4+ T
cells were added to the coating plate (1 × 105 cells/well).
C60-P, C60(OH)36, or NAC was added to the well 30 min
before the addition of anti-CD28 (1 μg/mL). After incu-
bation of the cells for 3 days at 37 °C (95 % room air,
5 % CO2), the amount of IL-2 released into an aliquot of
culture supernatant was measured with an IL-2 ELISA
kit (eBioscience) in accordance with the manufacturer’s
instructions.
Class-Switch Assays
B cells were purified from splenocytes by positive
selection with CD19 MicroBeads (Miltenyi Biotec) in
accordance with the manufacturer’s instructions. B
cell purity was determined by flow cytometry (B220+
cells >90 % purification). Immediately after cell prep-
aration, B cells were seeded into 96-well flat-bottom
plates (Nunc) (1 × 106 cells/well). B cells were incu-
bated in complete RPMI1640 with 10 ng/mL IL-4 and
3 μg/mL anti-CD40 for 10 days. C60-P, C60(OH)36, or
NAC was added to the wells 30 min before the
addition of IL-4 and anti-CD40. After incubation of
the cells for 10 days at 37 °C (95 % room air, 5 %
CO2), the amount of total IgE released into an aliquot
of culture supernatant was measured with a total IgE
ELISA kit (BD Biosciences) in accordance with the
manufacturer’s instructions.
In Vivo Treatment with a Mixture of C60-P and Antigen
C57BL/6 mice were treated weekly with OVA
(10 μg/mouse), LPS (30 μg/mouse), or NP49-Ficoll
(50 μg/mouse), or with a mixture of one of these
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plus C60-P (62.5 to 250 μg/kg), by intraperitoneal injection.
Seven days after the third (in the case of the OVA
experiment) or second (in the case of the LPS and NP-
Ficoll experiments) treatments, the blood or blood and
spleens, were collected to evaluate antibody responses and
effector cytokine responses. Splenocytes (1 × 106 cells/well)
were re-stimulated with OVA (100 μg mL). After
incubation of the cells for 72 h at 37 °C, the levels of IL-4
released into an aliquot of culture supernatant were
measured by ELISA (eBioscience) in accordance with the
manufacturer’s instructions.
Detection of Antigen-Specific Antibodies
Plasma levels of antigen-specific antibodies were
determined by ELISA. To detect OVA-specific IgG1,
LPS, or NP-specific IgM or IgG3, we coated ELISA
plates (Maxisorp; Nunc) with OVA (10 μg/mL), LPS
(25 μg/mL), or NP30-BSA (5 μg/mL). The coated plates
were incubated with 2 % Block Ace (for OVA-coated
plates) (Dainippon Sumitomo Pharmaceuticals, Osaka,
Japan) or 1 % BSA (for LPS or NP30-BSA-coated plates)
for 2 h at room temperature. Plasma dilutions were
added to the antigen-coated plates. After incubation
with the plasma for 2 h at room temperature, the coated
plates were incubated with a horseradish peroxidase-
conjugated goat anti-mouse IgG1, IgM, or IgG3 solution
(SouthernBiotech, Birmingham, AL, USA) for 2 h at
room temperature. After the incubation, the color reac-
tion was developed with tetramethylbenzidine (Moss,
Inc.; Pasadena, MD, USA), stopped with 2 N H2SO4, and
measured at OD450–620 on a microplate reader. To detect
OVA-specific IgE, we coated ELISA plates with purified
rat anti-mouse IgE (2 μg/mL) and detected OVA-specific
IgE with biotin-conjugated OVA (5 μg/mL) followed by
horseradish peroxidase-coupled streptavidin (Southern
Biotechnology Associates, Birmingham, AL).
Statistical Analysis
Statistical analyses were performed with Ekuseru-Toukei
2012 software (Social Survey Research Information Co.,
Ltd., Tokyo, Japan). Significant differences between
control groups and C60-P-added groups were deter-
mined by using the Williams test; a P value less than
0.05 was considered significant.
Results
Effects of C60 Derivatives on T cells In Vitro
We used two hydrophilized C60 derivatives, namely C60-P
and C60(OH)36, which had shown the strongest anti-
inflammatory effects among more than 20 C60 derivatives
that we had screened by using IL-1β-stimulated Caco-2
cells (human colon epithelial carcinoma cells) (paper in
preparation). In a preliminary experiment, to evaluate the
immune suppressive effects of C60-P and C60(OH)36, we
evaluated the cytotoxicity of the C60 derivatives on murine
splenocytes by using a lactate dehydrogenase assay. After
3 days’ co-incubation with each C60 derivative, no cytotox-
icity was induced by either one, at least at the maximum
dose that we used, 100 μM (data not shown). We there-
fore used 100 μM of each C60 derivative as the maximum
dose in the following in vitro assays.
The MLR is one of the assays most commonly used to
evaluate the T cell-mediated immune suppressive effects
of chemicals and is essentially based on the alloantigen-
specific T cell immune response. We first evaluated the
effect of C60 derivatives on T cells by using MLR and
measured IL-2 as a mediator of T cell expansion. C60-P
and C60(OH)36 dose-dependently suppressed IL-2 pro-
duction by responder cells (Fig. 1a). Thus, both C60 de-
rivatives had some T cell-suppressive effect. Next, each
C60 derivative was added to splenocytes with OVA in a
model of antigen-immunized splenocyte culture to
evaluate the effects of the derivatives on the OVA-
specific T cell immune response. IL-4 production in-
duced by OVA-re-stimulated splenocytes was signifi-
cantly reduced by C60-P treatment (Fig. 1b), but not by
C60(OH)36. To confirm the effect of C60-P on T cells,
CD4+ T cells were purified from splenocytes and then
stimulated with anti-CD3 and anti-CD28. To some
groups of CD4+ T cells, we added each C60 derivative or
the antioxidant NAC at various concentrations 30 min
before the addition of anti-CD28 antibodies. IL-2 pro-
duction induced by anti-CD3 and anti-CD28 stimulation
was decreased by both C60 derivatives (Fig. 1c). We con-
cluded that the C60 derivatives had T cell-suppressive ef-
fects in vitro at least. In addition, NAC suppressed IL-2
production, suggesting that the effects of C60 derivatives
on T cells were related to their antioxidant properties.
Effects of C60 Derivatives on B cells In Vitro
We evaluated the effects of the C60 derivatives on anti-
body production by B cells in vitro by using a class-
switch assay. Briefly, CD19+ B cells were purified from
splenocytes and incubated with IL-4 and anti-CD40 for
10 days to provoke their differentiation into IgE-
producing plasma cells. We added one of the C60 deriva-
tives or NAC at various concentrations 30 min before
adding the IL-4 and anti-CD40. We evaluated the effects
of both C60 derivatives on antibody production by meas-
uring IgE levels in the culture supernatant on day 10.
Both C60 derivatives dose-dependently suppressed IgE
production (Fig. 2); the effects of C60-P appeared more
potent than those of C60(OH)36. Our results suggested
that the C60 derivatives had some suppressive effects on
B cells. In addition, NAC treatment significantly de-
creased IgE levels, suggesting that the decrease in IgE
production caused by the C60 derivatives is associated
with their antioxidant properties.
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Fig. 2 Effects of C60 derivatives on B cell responses. C60-P, C60(OH)36, or N-acetylcysteine (NAC) was added to purified B cells 30 min before the
addition of IL-4 and anti-CD40. After incubation of the cells for 10 days, the amount of total IgE in the supernatants was measured by ELISA. Data




Fig. 1 Effects of C60 derivatives on T cell responses. a C60-P or C60(OH)36 was added to responder splenocytes 30 min before the addition of
stimulator splenocytes. After incubation of the cells for 4 days, the amount of IL-2 in the supernatants was measured by ELISA. b One week after
the third immunization with OVA and alum, mice were euthanized and single-cell suspensions of splenocytes were prepared. C60-P or C60(OH)36
was added to the wells 30 min before the addition of OVA (100 μg/mL). After incubation of the cells for 3 days, the amount of IL-4 in the
supernatants was measured by ELISA. c Purified CD4+ T cells were added to anti-CD3-coated plates. Each C60 derivative or N-acetylcysteine (NAC)
was added to the wells 30 min before the addition of anti-CD28. After incubation of the cells for 3 days, the amount of IL-2 in the supernatants
was determined by ELISA. Data are means ± SDs for three to six independent cultures (n = 3 to 6). *P < 0.05 vs. control group
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Effects of C60-P on the Acquired Immune Response In
Vivo
Our in vitro evaluation of the effects of the C60 deriva-
tives revealed that both had the potential to suppress T
and B cells; overall, C60-P seemed to have more potent
effects than C60(OH)36 (Figs. 1 and 2). In the next part
of our experiment, we therefore used C60-P to evaluate
the effects on the acquired immune response to OVA in
vivo. Mice were treated either with OVA alone or with
C60-P plus OVA every week for 3 weeks by intraperito-
neal injection. One week after the last treatment, we
evaluated OVA-specific antibody production and the T
cell immune response. OVA treatment alone induced
OVA-specific IgG1 and IgE production (Fig. 3a). Both
OVA-specific IgG1 and IgE levels were decreased by co-
administration of C60-P in a dose-dependent manner. In
addition, IL-4 production by OVA-re-stimulated spleno-
cytes from OVA + C60-P-treated mice was significantly
lower (when 250 μg/kg was used) than that in mice
treated with OVA alone (Fig. 3b). These findings showed
that C60-P could exert suppressive effects on the ac-
quired immune response in vivo.
Antibody production is classified as T dependent or T
independent on the basis of the requirement for T cell
help in antibody production [16]. T-dependent antigens
are proteins such as OVA, and production of OVA-
specific antibodies needs the cognate help of OVA-
specific T cells. In contrast, the T-independent antibody
response requires only B cell activation. To gather
mechanistic information on the in vivo effects of C60-
P—particularly in regard to whether they were solely B
cell effects—we evaluated the effects of C60-P on T cell-
independent antibody production. Because T-
independent antigens are categorized into types I and II
according to their B cell-activating mechanisms, we used
LPS as the type I antigen and NP-Ficoll as the type II
antigen. Mice were immunized with either LPS or NP49-
Ficoll alone or with either of these plus C60-P weekly for
2 weeks. One week after the last immunization, we eval-
uated the levels of LPS- or NP-specific IgM and IgG3 as
T-independent antibodies. Levels of LPS-specific IgM or
IgG3 induced by LPS injection were not affected by co-
injection of C60-P (Fig. 4a). Similarly, levels of NP-
specific IgM or IgG3 induced by NP49-Ficoll were not
a
b
Fig. 3 Effects of C60-P on acquired immune response to ovalbumin (OVA) in vivo. C57BL/6 mice were treated weekly with OVA alone (10 μg/mouse)
or with a mixture of C60-P at varying dose rates and OVA by intraperitoneal injection. Seven days after the last treatment, spleens and plasma were
collected. a Levels of OVA-specific IgG1 and IgE in the plasma were evaluated by ELISA. b Splenocytes were re-stimulated with OVA (100 μg mL). After
incubation of the cells for 72 h, levels of IL-4 in the supernatants were measured by ELISA. Data are means ± SEMs (n = 4 or 5). *P < 0.05 vs. OVA
alone group
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significantly changed by C60-P (Fig. 4b). Thus, the in
vivo suppressive effect of C60-P on the acquired immune
response could not be explained by a simple direct in-
hibitory effect on B cell activation.
Discussion
According to our in vitro results, our C60 derivatives
appeared to have a kind of direct suppressive effect on T
cell and B cell activation (Figs. 1 and 2), and C60-P co-
administered with OVA suppressed the OVA-specific
immune response in vivo. Both derivatives had suppres-
sive effects on T and B cells, suggesting that the suppres-
sive effects on acquired immunity might not be confined
to particular fullerene derivatives but might be general
properties related to the special structure of these
molecules.
Reactive oxygen species (ROS) are important messen-
gers in TCR signaling [17, 18]; suppression of the signal-
ing role of ROS is consistent with the suppressive effect
of NAC on T cells (Fig. 1c). The strong antioxidant
properties of fullerene derivatives may enable them to
work as antioxidants for T cells, suppressing TCR signal-
related activation and proliferation (Fig. 1). In addition,
both of our C60 derivatives and NAC suppressed IgE
production by B cells (Fig. 2). B cell activating signaling
via CD40 is dependent on ROS production [19]. Thus, B
cell activation and class-switching may depend on ROS,
and our C60 derivatives therefore suppressed B cells via
their antioxidant properties. To summarize, the in vitro
effects of the derivatives on both T cells and B cells are
likely due to their antioxidant properties.
In contrast, in vivo, C60-P successfully suppressed
OVA-specific immune responses, which require T cells
(Fig. 3), but it did not suppress T cell-independent anti-
body production (Fig. 4). CD40 ligation on B cells, which
is provided by T cells, is not needed for T cell-
independent antibody production. Thus, the in vitro re-
sults for B cells cannot be extrapolated directly to the re-
sults regarding T cell-independent antibody production
in vivo. These findings would be in conflict if the in vivo
suppressive effect on the OVA-specific immune response
were induced by the targeting of B cells or by the anti-
oxidant properties of the derivatives alone. C60-P likely
exists as aggregates or agglomerates of varying sizes
(transmission electron microscopic observations by an-
other group have revealed an average size of C60-P of
a
b
Fig. 4 Effects of C60-P on T cell-independent antibody responses in vivo. C57BL/6 mice were treated weekly with lipopolysaccharide (LPS)
(30 μg/mouse) or NP49-Ficoll (50 μg/mouse) alone or with a mixture of C60-P at varying dose rates and LPS or NP49-Ficoll by intraperitoneal injection.
Seven days after the second treatment, plasma was collected. Levels of LPS-specific (a) or NP-specific (b) IgM and IgG3 were evaluated by ELISA. Data
are means ± SEMs (n = 5). *P < 0.05 vs. LPS or NP49-Ficoll alone group
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45.6 ± 18.8 nm; [20]). Nanoparticles of that size are
probably primarily ingested by macrophages/Kupffer
cells in vivo [21]; thus, direct interaction between C60-P
and T or B cells is less likely to occur in our in vivo ex-
perimental system than in our in vitro system. We there-
fore speculate that the pharmacokinetics of C60-P were
responsible for the discrepancy between its in vivo and
in vitro effects. Further studies are needed to conclu-
sively identify the cellular and molecular mechanisms of
the effects of C60-P in vivo.
The acquired immune response is essentially the result
of complex interactions among T cells, B cells, and den-
dritic cells (DCs). C60 and C60-P have been suggested to
promote antigen presentation by DCs by another group
[20]. C60(OH)36, which might have weaker suppressive
effects than C60-P on T and B cells, failed to suppress
OVA-specific IL-4 production by OVA-immunized sple-
nocytes (Fig. 1b). In that assay, antigen-presentation by
the DC and macrophage components of splenocytes
played a critical role in inducing OVA-specific IL-4 pro-
duction. Thus, the effects of C60(OH)36 on T cells and
DCs might have canceled each other out. Thus, it is pos-
sible that C60 derivatives inconsistently affect each as-
pect of the acquired immune response in vivo. However,
considering the ultimate phenotype of the OVA-specific
immune response induced by C60-P in vivo appeared to
be suppressive (Fig. 3), together we may say that fuller-
ene derivatives can be suppressive reagents for acquired
immune responses in vivo.
Conclusions
Our data suggest that fullerene derivatives can suppress
acquired immune responses that require T cells. Some
groups have attempted to use fullerenes as tumor-
inhibitory reagents by activating anti-tumor immunity
[22, 23]. With this use, the suppression of acquired im-
munity by the fullerene can be a side effect. Because ful-
lerene derivatives may have variable efficacies and may
have the potential to have conflicting actions in some
situations like a conflict of effect on DC, T, and B cells
above, future studies to elucidate the molecular mecha-
nisms of their efficacy are needed so that we can take
full advantage of their beneficial effects in each situation.
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